Brain insulin receptor signaling as a targetable intervention for neuroinflammation in alzheimer's disease

Overview

Brain insulin resistance is a prominent feature of Alzheimer's disease, present in over 90% of affected individuals, yet its role in driving neuroinflammation has been poorly understood. This research program investigates brain insulin receptor signaling as a regulator of neuroinflammatory responses and a potential intervention point for Alzheimer's disease. Preliminary findings in healthy adult mice demonstrate that acute loss of brain insulin receptor signaling, achieved via intranasal delivery of the insulin receptor antagonist S961, alters inflammatory status and blood-brain barrier permeability in response to an inflammatory stimulus. The resulting data suggest that brain insulin resistance modulates the inflammatory cascade and may serve as a targetable mechanism for reducing neuroinflammation associated with Alzheimer's disease.

Technical specifications

• Intranasal delivery platform: A single intranasal administration of the insulin receptor antagonist S961 delivers and distributes the substrate throughout the brain, confirmed by radioactive tracer techniques.
• Inflammatory challenge model: Intraperitoneal lipopolysaccharide (LPS) administration induces a systemic inflammatory response used to evaluate blood-brain barrier permeability and cytokine responses.
• Blood-brain barrier assessment: Radioactive tracer methods quantify changes in blood-brain barrier permeability following insulin receptor blockade and inflammatory challenge.
• Peripheral inflammation profiling: Serum amyloid A (SAA) and multiplex cytokine/chemokine ELISAs, including IL-2, RANTES, MCP-1, and GM-CSF, characterize the peripheral inflammatory response.
• Key preliminary finding: Mice receiving intranasal S961 prior to LPS showed reduced blood-brain barrier permeability and decreased serum inflammatory markers compared to LPS alone, suggesting a protective effect of acute brain insulin receptor blockade against inflammatory challenge.
• Planned extensions: Future studies will measure brain cytokines and neuroinflammation markers such as GFAP and IBA1, and will assess peripheral glucose/insulin tolerance and serum metabolic hormones to fully characterize the metabolic phenotype of the model.

Technology readiness level

The research is currently at an early preclinical stage. Proof-of-concept data have been generated in healthy adult mice (n=10 per group) demonstrating that acute brain insulin receptor antagonism modulates inflammatory responses and blood-brain barrier permeability. The team is seeking collaborative partnerships to extend these findings by assessing neuroinflammatory markers directly in brain tissue and characterizing the metabolic phenotype, including extension into Alzheimer's disease mouse models. These follow-up studies are projected to be completable within one year and will help establish a new preclinical model for brain insulin resistance with relevance to Alzheimer's disease.